← The Polylog AI Intelligence Brief
Morning Edition · Tuesday, August 11, 2026Published at 2:26 AM EDT · New York
Hassabis Leaves the DeepMind Chief Executive Role as Jeff Dean Departs Google
Koray Kavukcuoglu takes over daily operations of the lab behind Gemini, while Hassabis becomes Alphabet chief scientist and concentrates on Isomorphic Labs.
Demis Hassabis, the Nobel laureate who co-founded DeepMind and ran it through the Gemini era, is stepping down as chief executive and becoming chair of Google DeepMind plus chief scientist of Alphabet. Koray Kavukcuoglu, previously the lab's chief technology officer, takes over daily operations as senior vice president. Hassabis continues to lead Isomorphic Labs, Alphabet's drug-discovery company.
The reshuffle is broader than one title. Jeff Dean, a 27-year Google veteran and most recently chief scientist at Google DeepMind, is leaving with several colleagues to start a public-benefit corporation called Discovery Loop. Losing the person who built much of Google's machine-learning infrastructure at the same moment the founding chief executive moves to a part-time research role is a significant concentration of change in one organization.
Hassabis has framed the move around research rather than management. A widely circulated summary of his remarks reported by an AI news channel has him expecting all human diseases to be curable within twenty years, with Isomorphic Labs as the company meant to deliver it. That is a claim about a scientific timeline made by the person whose company would deliver it, and no peer-reviewed result supports a twenty-year figure. AlphaFold changed structural biology, but structure prediction and end-to-end therapeutic discovery are different problems with different failure modes.
What is verifiable is the organizational fact. Google DeepMind now runs day to day under an engineer rather than its founder, at a point when Fortune described the changes as a major leadership restructuring across Alphabet's artificial intelligence effort.
Veracity: Corroborated
88/100- If true, who benefits
Alphabet keeps a Nobel laureate's name attached to its research effort while handing product control to an engineer accountable for Gemini shipping, and Isomorphic Labs benefits from a curative timeline that supports the valuation behind its .
Part of a tracked trend
AI Moves Into Autonomous Scientific Discovery and Clinical Care
Over the next 3-9 months, AI systems move beyond text tasks into running real scientific experiments and managing clinical care, backed by peer-reviewed and benchmarked evidence of chemist- and physician-level performance.
Townsquare
Start a discussion in Townsquare.
More from this edition
- OpenAI Ships a Purpose-Trained Offensive Security Model to Vetted Partners Only
- Meta Superintelligence Labs Returns to Open Weights With a 30B Agent Model Under Apache 2.0
- Agent Tooling Fights Its Own Token Overhead as Qwen Ships a Harness-Agnostic Multimodal Layer
- Three New Papers Attack the Weak Points of Multimodal Models at Once
- Researchers Test Whether Claude Models Write Code That Passes a SOC 2 Audit
- Schmidt Puts Frontier Training Runs at $200m to $500m With a Six-Month Useful Life
- Texas Halts New Data Center Grid Approvals as Requests Reach 474 Gigawatts
Comments
0No comments yet.